• Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8562478).
  

PubMed=8562478
Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T.M., Gudas J.M., Bates S.E.
Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Cell Growth Differ. 6:1395-1403(1995)

PubMed=9815641
Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.
Altered gene expression in drug-resistant human breast cancer cells.
Clin. Cancer Res. 3:2405-2414(1997)

PubMed=10995814; DOI=10.1093/jnci/92.18.1535
Pirnia F., Breuleux M., Schneider E., Hochmeister M., Bates S.E., Marti A., Hotz M.A., Betticher D.C., Borner M.M.
Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53.
J. Natl. Cancer Inst. 92:1535-1536(2000)

PubMed=14871996; DOI=10.1158/1078-0432.ccr-1044-3
Hu Y.-P., Krishan A., Nie W.-J., Sridhar K.S., Mayer L.D., Bally M.
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Clin. Cancer Res. 10:1160-1169(2004)